<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Clin Risk Manag</journal-id><journal-id journal-id-type="iso-abbrev">Ther Clin Risk Manag</journal-id><journal-id journal-id-type="publisher-id">Therapeutics and Clinical Risk Management</journal-id><journal-title-group><journal-title>Therapeutics and Clinical Risk Management</journal-title></journal-title-group><issn pub-type="ppub">1176-6336</issn><issn pub-type="epub">1178-203X</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28721055</article-id><article-id pub-id-type="pmc">5499789</article-id><article-id pub-id-type="doi">10.2147/TCRM.S134039</article-id><article-id pub-id-type="publisher-id">tcrm-13-739</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Lijie</given-names></name><xref ref-type="aff" rid="af1-tcrm-13-739">1</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Tingli</given-names></name><xref ref-type="aff" rid="af2-tcrm-13-739">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lina</given-names></name><xref ref-type="aff" rid="af1-tcrm-13-739">1</xref><xref ref-type="corresp" rid="c1-tcrm-13-739"/></contrib></contrib-group><aff id="af1-tcrm-13-739"><label>1</label>Department of Geriatrics</aff><aff id="af2-tcrm-13-739"><label>2</label>Department of Nephrology, General Hospital of Daqing Oil Field, Daqing, China</aff><author-notes><corresp id="c1-tcrm-13-739">Correspondence: Lina Wang, Department of Geriatrics, General Hospital of Daqing Oil Field, No 9 Zhongkang Street, Daqing 163311, China, Tel +86 459 580 5175, Email <email>wanglina517@126.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>27</day><month>6</month><year>2017</year></pub-date><volume>13</volume><fpage>739</fpage><lpage>750</lpage><permissions><copyright-statement>&#x000a9; 2017 Zhao et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2017</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><p>Sitagliptin improves glycemic control in type 2 diabetes mellitus (T2DM) patients but its side effects are undesirable. Chitosan oligosaccharide (COS) is expected to improve the therapeutic result as a natural product. A total of 200 elderly T2DM patients were evenly assigned into four groups: sitagliptin group (SG), receiving sitagliptin 100 mg/day; COS group (CG), receiving COS 100 mg/day; combination therapy of sitagliptin and COS group (SCG), receiving both sitagliptin and COS 100 mg/day; and placebo group (PG), receiving placebo 100 mg/day. After 42-week therapy, biochemical indices and clinical parameters for the alterations from start points were analyzed. The related molecular mechanism was tested by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot at cell level. Lower risk of hypoglycemia was found in the SCG group when compared with SG and other groups (<italic>P</italic>&#x0003c;0.05). More patients from the SCG group than other groups attained hemoglobin A1c (HbA1c) reduction &#x0003e;2.5% (<italic>P</italic>&#x0003c;0.05). Weight reduction of 1.2&#x000b1;0.9, 2.6&#x000b1;0.8, 4.7&#x000b1;1.3, and 0.9&#x000b1;0.6 kg was observed in the patients from SG, CG, SCG, and PG groups, respectively (<italic>P</italic>&#x0003c;0.05). The combined treatment of COS and sitagliptin presented better therapeutic results by improving insulin sensitivity, lipid profile, adiponectin levels, and glucagon-like peptide 1 and reducing side effects, insulin resistance, HbA1c, body mass index, resistin, tumor necrosis factor (TNF)-&#x003b1;, and C-reactive protein (CRP) (<italic>P</italic>&#x0003c;0.05). qRT-PCR and Western blot analysis also showed that COS treatment reduced the levels of resistin, TNF-&#x003b1;, and CRP, and increased the level of adiponectin. The combination of COS and sitagliptin provided better glycemic control with fewer side effects and with more weight reduction in the elderly participants with T2DM.</p></abstract><kwd-group><title>Keywords</title><kwd>C-reactive protein</kwd><kwd>glucagon-like peptide 1</kwd><kwd>chitosan oligosaccharide</kwd><kwd>sitagliptin</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>insulin sensitivity</kwd><kwd>adiponectin</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Type 2 diabetes mellitus (T2DM) is prevalent in the elderly population, has been widely reported, and increases with human aging.<xref rid="b1-tcrm-13-739" ref-type="bibr">1</xref> The number of T2DM patients in the elderly population is expected to reach 120 million by 2030.<xref rid="b2-tcrm-13-739" ref-type="bibr">2</xref> It has been well known that poor glucose control is associated with elderly T2DM patients. However, glycemic control in the elderly population proposes a big challenge. In this population, the incidences of hypoglycemia increase while hypoglycemia is related to increasing morbidity,<xref rid="b3-tcrm-13-739" ref-type="bibr">3</xref>,<xref rid="b4-tcrm-13-739" ref-type="bibr">4</xref> which significantly affects the quality of life of patients.</p><p>In the therapy of elderly T2DM patients, insulin and oral antidiabetic drugs have occupied a high proportion of adverse event-related drugs. Sitagliptin, an important dipeptidyl peptidase-4 inhibitor,<xref rid="b5-tcrm-13-739" ref-type="bibr">5</xref> improves glycemic control, and is often combined with metformin<xref rid="b6-tcrm-13-739" ref-type="bibr">6</xref> or pioglitazone.<xref rid="b7-tcrm-13-739" ref-type="bibr">7</xref> In the study of elderly patients with T2DM, glycemic controls can be achieved by using sitagliptin.<xref rid="b8-tcrm-13-739" ref-type="bibr">8</xref></p><p>There are some side effects for sitagliptin therapy of T2DM although it has been widely used. T2DM patients using sitagliptin may develop rhinorrhea, cough, dyspnea, and tiredness and these symptoms disappear immediately after the medicine is stopped.<xref rid="b9-tcrm-13-739" ref-type="bibr">9</xref> Furthermore, although sitagliptin can lower glucose concentration effectively, its long-term use can cause some adverse effects, such as infections, depression, and cancer.<xref rid="b10-tcrm-13-739" ref-type="bibr">10</xref></p><p>Chitosan oligosaccharide (COS), as a depolymerized product of chitosan, has received much attention in the biomedical, food, pharmaceutical, and environmental industries because of its biocompatible and biodegradable properties.<xref rid="b11-tcrm-13-739" ref-type="bibr">11</xref> COS has antioxidative,<xref rid="b12-tcrm-13-739" ref-type="bibr">12</xref> anti-inflammatory,<xref rid="b13-tcrm-13-739" ref-type="bibr">13</xref> and antibacterial bioactivities.<xref rid="b14-tcrm-13-739" ref-type="bibr">14</xref> It has the potential to treat age-related dysfunctions including oxidative stress and chronic inflammation.<xref rid="b15-tcrm-13-739" ref-type="bibr">15</xref> Catheter-induced infection and healthcare-related infection increase the mortality rate and hospital charges. COS is found to control the incidence of healthcare-associated infection.<xref rid="b16-tcrm-13-739" ref-type="bibr">16</xref> A number of publications have been devoted to the antidiabetic effect of COS. For instance, low molecular weight COS has the potential for hyperglycemia management and provides a strong rationale for T2DM prevention via COS.<xref rid="b17-tcrm-13-739" ref-type="bibr">17</xref> COS can help control postprandial glucose in subjects with prediabetes.<xref rid="b18-tcrm-13-739" ref-type="bibr">18</xref> COS demonstrates its antidiabetic effect by inhibiting the expression of intestinal &#x003b1;-glucosidase, glucose transporters, and peroxisome proliferator-activated receptor &#x003b3;.<xref rid="b19-tcrm-13-739" ref-type="bibr">19</xref> More importantly, COS can be widely used as a medicine delivery system with fewer side effects.<xref rid="b20-tcrm-13-739" ref-type="bibr">20</xref> Therefore, it is believed that COS may improve the therapeutic results of sitagliptin in the therapy of elderly patients with T2DM.</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="methods"><title>Mass analysis of COS using matrix-assisted laser desorption/ionization&#x02013;time-of-flight (MALDI-TOF)</title><p>COS, with a mean molecular weight of 5 kDa and deacetylated degree &#x0003e;90%, was prepared as per earlier reports.<xref rid="b21-tcrm-13-739" ref-type="bibr">21</xref> Briefly, 100 g shrimp shell was deproteinized in 1 L NaOH solution (1 M) for 1 day, and then demineralized in HCl (1 M) for 1 day. Pigments and lipid were removed by using 95% ethanol at 70&#x000b0;C. Chitin was deacetylated in 50% (w/w) NaOH solution until 90% degree of deacetylation was obtained. Low-level degree of polymerization (DP) of COS was prepared according to a previous report with some modification.<xref rid="b22-tcrm-13-739" ref-type="bibr">22</xref> Chitosan (100 mL, 1% [v/w], pH 6.0) was added with 20 &#x000b5;L recombinant chitosanase. After incubation for 30 minutes at 39&#x000b0;C, hydrolysis reactions were terminated by boiling for 15 minutes, cooling, and centrifugation to remove insoluble chitosan. Samples (1 &#x000b5;L) and 2 &#x000b5;L 2,5-dihydroxybenzoic acid (15 mg/mL) were added to 30% ethanol. Mass spectra were observed on an Agilent 6530 accurate-mass system (Agilent Technologies, Santa Clara, CA, USA). The spectrum was examined via external calibration.</p></sec><sec sec-type="subjects"><title>Participants</title><p>All procedures were confirmed and approved by the Ethics Committee of General Hospital of Daqing Oil Field (approval no DQ201305X26) on April 6, 2013. All steps were performed according to the Declaration of Helsinki.<xref rid="b23-tcrm-13-739" ref-type="bibr">23</xref> From May 2013 to August in 2014, 416 elderly T2DM patients (&#x02265;60 years) were recruited.</p></sec><sec><title>Inclusion criteria</title><p>Patients were included if 1) they had T2DM for &#x0003e;5 years; 2) their hemoglobin A1c (HbA1c) &#x0003c;10.5%; 3) their body mass index (BMI) &#x0003e;25 and &#x0003c;39 kg/m<sup>2</sup>; 4) they had stable weight for &#x0003e;3 months before the present experiment; 5) they had no other serious diseases; 6) their fasting plasma glucose (FPG) was &#x0003e;130 or &#x0003c;240 mg/dL.</p></sec><sec><title>Exclusion criteria</title><p>Patients were excluded from the study if they 1) had T1DM; 2) had renal function impairment; 3) had an FPG &#x0003e;270 mg/dL; 4) achieved weight loss by using medicines within 3 months before the present experiment; 5) had a family history of T2DM; and 6) if it was hard to chat with them.</p></sec><sec><title>Grouping</title><p>After selection using the above criteria, 200 elderly T2DM patients &#x02265;60 years of age were finally selected and randomized to consume sitagliptin 100 mg/day (sitagliptin group [SG]), COS 100 mg/day (COS group [CG]), the combination of sitagliptin 100 mg/day and COS 100 mg/day (sitagliptin and COS group [SCG]), or placebo 100 mg/day (placebo group [PG]), respectively. HbA1c data from all patients were recorded at the start of the study and all subjects were randomized and subjected to double-blind studies. All patients provided written informed consent to participate in the experiment.</p></sec><sec><title>Clinical characterization</title><p>Patients&#x02019; BMI was calculated by dividing weight (kg) by the square of height (m<sup>2</sup>). Other elements, such as weight, age, gender, lifestyle, and hypertension, were also noted in the present experiment.</p></sec><sec sec-type="methods"><title>Biochemical analysis</title><p>Capillary whole blood glucose levels were measured in all patients. Those with a capillary whole blood glucose level &#x0003e;6.1 mM were a higher risk of diabetes.<xref rid="b24-tcrm-13-739" ref-type="bibr">24</xref> The concentration of glucose and the level of HbAlc were tested after 2 hours following glucose intake. Serum glucose levels, basal blood glucose (BG), and fasting blood glucose (FBG) were measured by an EMP Medical-Chemistry Analyzer (Shenzhen Emperor Electronic Technology Co, Ltd, Shenzhen, China). HbAlc levels were measured by using affinity chromatography (GE Healthcare [Shanghai] Co, Ltd, Shanghai, China). Levels of total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-c) and low-density lipoprotein-cholesterol (LDL-c) were examined by using an assay kit (cat no ab65390; Abcam, Shanghai, China). Triglyceride (TG) levels were determined by using a Triglyceride Quantification Assay Kit (cat no ab65336; Abcam). Serum insulin was tested by Abcam&#x02019;s Insulin Simple Step Kit (cat no ab200011). Serum basal insulin (BINS) and fasting insulin (FINS) were examined by a radioimmunoassay kit (Shanghai Traditional Medicine University, Shanghai, China). Insulin resistance (HOMA-IR) indexes were calculated as HOMA-IR = FBG &#x000d7; FINS/22.5. Insulin secretory (HOMA-IS) activity was measured as HOMA-IS =20&#x000d7; FINS/(FBG-3.5). HOMA of &#x003b2;-cell activity (HOMA-B) was calculated as HOMA-B =20&#x000d7; BINS/(BG-3.5).</p></sec><sec><title>Enzyme-linked immunosorbent assay (ELISA) tests</title><p>The serum concentrations of target proteins were measured by using ELISA kits. Human C-reactive protein (CRP; cat no ab99995), human tumor necrosis factor-&#x003b1; (TNF-&#x003b1;; cat no ab46087), human adiponectin (cat no ab99968), human resistin (cat no ab100634), and human glucagon-like peptide 1 (GLP-1; cat no ab184857) were purchased from Abcam and analyses were performed.</p></sec><sec sec-type="methods"><title>Analysis of side effects at endpoints</title><p>The endpoint analysis included changes of HbA1c, FPG, and BMI from baseline. Side effects (fatigue,<xref rid="b9-tcrm-13-739" ref-type="bibr">9</xref> cough,<xref rid="b9-tcrm-13-739" ref-type="bibr">9</xref> headache,<xref rid="b25-tcrm-13-739" ref-type="bibr">25</xref> hypoglycemia,<xref rid="b26-tcrm-13-739" ref-type="bibr">26</xref> loss of consciousness,<xref rid="b26-tcrm-13-739" ref-type="bibr">26</xref> constipation,<xref rid="b27-tcrm-13-739" ref-type="bibr">27</xref> nausea,<xref rid="b27-tcrm-13-739" ref-type="bibr">27</xref> vomiting,<xref rid="b27-tcrm-13-739" ref-type="bibr">27</xref> and diarrhea<xref rid="b28-tcrm-13-739" ref-type="bibr">28</xref>) were measured. All patients had no such side effects before this study. Side effect scales were evaluated based on the frequency of experiences on a 5-point scale: never, seldom, sometimes, very often, and permanently.</p></sec><sec><title>Cell culture</title><p>Adipocytes 3T3-L1 and 3T3-F442A were obtained from Cell Bank of Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). All cells were cultured with Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM) in a 37&#x000b0;C incubator with 5% CO<sub>2</sub>. 3T3-L1 and 3T3-F442A cells were treated with 1 mg/L sitagliptin (SG), 1 mg/L sitagliptin and 1 mg/L COS (SCG), and cultured in DMEM for 72 hours.</p></sec><sec><title>Quantitative real-time polymerase chain reaction (qRT-PCR)</title><p>All cells were collected and RNA was isolated with an RNA purification kit (cat no KIT0312-I; Fisher Scientific, Waltham, MA, USA). The primers were designed as follows: CRP forward primer, 5&#x02032;-ctgtcctcgacccggggtac-3&#x02032;; CRP reverse primer, 5&#x02032;-tgtgtactggagctactgtg-3&#x02032; (160 bp); TNF-&#x003b1; forward primer, 5&#x02032;-tattatacccagccagcgcc-3&#x02032;; TNF-&#x003b1; reverse primer, 5&#x02032;-agccaggtcagagcaccggc-3&#x02032; (170 bp); adiponectin forward primer, 5&#x02032;-ggtgaaaccggagtacccgg-3&#x02032;; adiponec-tin reverse primer, 5&#x02032;-tggtaaagcgaatgggcatg-3&#x02032; (160 bp); resistin forward primer, 5&#x02032;-ctgtgctccatggaagaagc-3&#x02032;; resis-tin reverse primer, 5&#x02032;-ggtgacggcgaagcctcggg-3&#x02032; (130 bp); and GAPDH forward primer, 5&#x02032;-gtggtggctgtgaatgatcc-3&#x02032;; GAPDH reverse primer, 5&#x02032;-accacgtaggggctcccgac-3&#x02032; (200 bp). PCR was performed using the following protocol: denaturation at 94&#x000b0;C for 20 seconds, annealing at 55&#x000b0;C for 20 seconds, and extension at 72&#x000b0;C for 20 seconds, 40 cycles. PCR products were compared between SG and SCG.</p></sec><sec sec-type="methods"><title>Western blot analysis</title><p>Cell lines 3T3-L1 and 3T3-F442A were disrupted by hypotonic lysis in sterile water. Human CRP antibody AF1707, human TNF-&#x003b1; antibody MAB210-100, human adiponectin/Acrp30 antibody (AF1065), human resistin antibody MAB13591-100, and human GAPDH antibody MAB5718 were from R&#x00026;D Systems (Minneapolis, MN, USA).</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>The COS effect was evaluated at a two-sided <italic>P</italic>&#x0003c;0.05. Fisher&#x02019;s exact test was performed to compare categorical variables, including side effects events and incidences of hypoglycemia. Predefined analysis was performed to investigate variations in HbA1c and FBG. All data were presented as mean &#x000b1; standard deviation and analyzed by SPSS statistics 20.0 (IBM Corporation, Armonk, NY, USA). A <italic>P</italic>-value &#x0003c;0.05 was considered significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="methods"><title>COS analysis</title><p>MALDI-TOF mass spectrometry was used to analyze COS and the results showed that the main products for DP were DP3, 4, and 5 when potassium adduct ions were calculated in MALDI-TOF (<xref ref-type="fig" rid="f1-tcrm-13-739">Figure 1</xref>).</p></sec><sec sec-type="subjects"><title>Baseline characters of all participants</title><p>After selection, 200 T2DM elderly patients were selected. Fifty participants each in 4 groups received sitagliptin, COS, the combination of sitagliptin and COS, and placebo, respectively (<xref ref-type="table" rid="t1-tcrm-13-739">Table 1</xref>). The mean ages were 69.1&#x000b1;8.4, 67.8&#x000b1;7.5, 68.9&#x000b1;8.8, and 68.5&#x000b1;8.0 years in SG, CG, SCG, and PG groups, respectively. There was no statistical significance of differences for baseline characteristics among the four groups (<italic>P</italic>&#x0003e;0.05).</p></sec><sec><title>More weight loss in SCG group</title><p><xref ref-type="table" rid="t2-tcrm-13-739">Table 2</xref> showed that the combination therapy was superior than only sitagliptin and other groups (<italic>P</italic>&#x0003c;0.05). Subjects in the SCG group had more weight loss (<italic>P</italic>&#x0003c;0.01), with mean weight decreases of 1.2&#x000b1;0.9, 2.6&#x000b1;0.8, 4.7&#x000b1;1.3, and 0.9&#x000b1;0.6 kg in SG, CG, SCG, and PG groups, respectively (<xref ref-type="table" rid="t2-tcrm-13-739">Table 2</xref>). Similarly, patients demonstrated more BMI loss in the SCG group than in SG and other groups (<italic>P</italic>&#x0003c;0.05) (<xref ref-type="fig" rid="f2-tcrm-13-739">Figure 2A</xref>). For alterations in HbA1c after the 42-week trial, decreases occurred in the SCG group than in SG and other groups. There were significant differences for HbA1c levels between SCG and SG or other groups after 12-week therapy (<xref ref-type="fig" rid="f2-tcrm-13-739">Figure 2B</xref>, <italic>P</italic>&#x0003c;0.05).</p></sec><sec><title>Glucose values in SCG compared to SG group</title><p>As <xref ref-type="table" rid="t1-tcrm-13-739">Table 1</xref> shows, at 42-week trial, all subjects from the SCG group had lower mean glucose values than the ones from SG or other groups before breakfast and 2 hours post-breakfast (<italic>P</italic>&#x0003c;0.05). The findings imply that COS decreases the glucose values before breakfast and 2 hours post-breakfast.</p></sec><sec sec-type="methods"><title>Analysis of fasting c peptide (FCP) and 2-hour postprandial c peptide (PCP)</title><p>Results showed that there was no significant change for FCP and 2-hour PCP in the participants from SG to SCG groups (<italic>P</italic>&#x0003e;0.05) (<xref ref-type="table" rid="t2-tcrm-13-739">Table 2</xref>). The findings imply that COS cannot effect FCP and PCP.</p></sec><sec><title>Changes for resistin, CRP, TNF-&#x003b1;, and adiponectin</title><p>The levels of resistin, CRP, TNF-&#x003b1;, and insulin resistance were lower in the SCG group than in SG and other groups (<italic>P</italic>&#x0003c;0.05) (<xref ref-type="table" rid="t2-tcrm-13-739">Table 2</xref>). Resistin is an important marker for diabetes. It increases in fat persons and anti-resistin therapy reduces blood sugar and increases insulin in animal models. Combined treatment resulted in a higher reduction in resistin concentration from the SCG group than from SG and other groups (<italic>P</italic>&#x0003c;0.05). There were significant differences for resistin concentration among the four groups since the 24th week (<xref ref-type="fig" rid="f3-tcrm-13-739">Figure 3A</xref>, <italic>P</italic>&#x0003c;0.05).</p><p>CRP is associated with inflammation and an important biomarker for the development of diabetes.<xref rid="b29-tcrm-13-739" ref-type="bibr">29</xref> In this study, combined treatment resulted in a higher reduction in the CRP concentration in SCG than in SG and other groups (<italic>P</italic>&#x0003c;0.05). There were significant differences for CRP levels between SCG and SG and/or other groups since the 24th week (<xref ref-type="fig" rid="f3-tcrm-13-739">Figure 3B</xref>, <italic>P</italic>&#x0003c;0.05).</p><p>TNF-&#x003b1; is an inflammatory cytokine and plays a critical role in insulin resistance. It is found to be at a higher level in lipid tissue.<xref rid="b30-tcrm-13-739" ref-type="bibr">30</xref> Combined treatment resulted in a greater reduction of TNF-&#x003b1; in SCG than in SG and other groups (<italic>P</italic>&#x0003c;0.05). There were significant differences for TNF-&#x003b1; between SCG and SG and/or other groups at 24th week (<xref ref-type="fig" rid="f3-tcrm-13-739">Figure 3C</xref>, <italic>P</italic>&#x0003c;0.05).</p><p>Insulin sensitivity was significantly increased in SG and SCG groups (<italic>P</italic>&#x0003c;0.05). Adiponectin improves insulin sensitization and anti-inflammation and the lower expressed protein increases the resistance of insulin in fat and diabetic persons.<xref rid="b31-tcrm-13-739" ref-type="bibr">31</xref> The levels of adiponectin are lower in T2DM patients than in healthy participants.<xref rid="b32-tcrm-13-739" ref-type="bibr">32</xref> The combined method resulted in a higher improvement of adiponectin concentration in SCG than in SG and other groups (<italic>P</italic>&#x0003c;0.05). Significant differences were found between SCG and SG and other groups since the 24th week (<xref ref-type="fig" rid="f3-tcrm-13-739">Figure 3D</xref>, <italic>P</italic>&#x0003c;0.05).</p></sec><sec><title>Serum concentration of GLP-1</title><p><xref ref-type="fig" rid="f4-tcrm-13-739">Figure 4</xref> shows that there is no statistical significance of differences for serum concentration of GLP-1 among the four groups (<italic>P</italic>&#x0003e;0.05). Comparatively, sitagliptin and/or COS reduced the serum concentration of GLP-1 markedly (<italic>P</italic>&#x0003c;0.05). Furthermore, the combination of sitagliptin and COS reduced the serum concentration of GLP-1 more than the other groups (<italic>P</italic>&#x0003c;0.05).</p></sec><sec><title>Changes of lipid profile</title><p>Lipid profile is an important parameter for health. As <xref ref-type="table" rid="t1-tcrm-13-739">Table 1</xref> showed, TG, TC, and LDL was decreased in HDL was increased in SG, CG and SCG groups (<italic>P</italic>&#x0003c;0.05). Comparatively, higher decreases in the levels of TG, TC, and LDL were found in the SCG than SG group (<italic>P</italic>&#x0003c;0.05) (<xref ref-type="table" rid="t2-tcrm-13-739">Table 2</xref>). The present finding suggests that combined treatment reduced the levels of TG, TC, and LDL more in SCG than in the SG group (<italic>P</italic>&#x0003c;0.05). COS improves the lipid profiles of elderly T2DM patients. In PG, there was no significant change for lipid profiles (<italic>P</italic>&#x0003e;0.05).</p></sec><sec><title>Combination therapy improves HOMA-IS and HOMA-IR</title><p>The participants in SCG group showed improved &#x003b2;-cell function. HOMA-IS indexes were enhanced from 69.1&#x000b1;29.8 (baseline) to 91.6&#x000b1;43.8 in the SCG group, from 68.4&#x000b1;37.4 (baseline) to 80.3&#x000b1;54.2 in the SG group (<italic>P</italic>&#x0003c;0.05), from 69.7&#x000b1;38.6 (baseline) to 78.3&#x000b1;50.9 in the CG group (<italic>P</italic>&#x0003c;0.05), and from 68.8&#x000b1;32.7 (baseline) to 70.3&#x000b1;52.3 in the PG group (<italic>P</italic>&#x0003e;0.05) after the 42-week trial. Conversely, <xref ref-type="table" rid="t1-tcrm-13-739">Table 1</xref> shows that the HOMA-IR indexes were reduced from 6.6&#x000b1;3.5 to 4.5&#x000b1;2.5 in the SCG group, from 6.3&#x000b1;3.2 (baseline) to 5.8&#x000b1;2.4 in the SG group (<italic>P</italic>&#x0003c;0.05), from 6.4&#x000b1;2.8 (baseline) to 6.0&#x000b1;2.4 in the CG group (<italic>P</italic>&#x0003e;0.05), and from 6.5&#x000b1;3.0 (baseline) to 6.3&#x000b1;2.9 in the PG group (<italic>P</italic>&#x0003e;0.05) after the 42-week trial. Combined treatment showed a better therapeutic result for &#x003b2;-cell function by affecting the sensitivity and resistance of insulin.</p></sec><sec><title>Experiences of side effects</title><p>The side effect of sitagliptin was assessed according to the scales in <xref ref-type="table" rid="t3-tcrm-13-739">Table 3</xref>. Patients experienced fatigue, cough, headache, hypoglycemia, loss of consciousness, constipation, nausea, vomiting, and diarrhea as reported in their interviews. <xref ref-type="table" rid="t3-tcrm-13-739">Table 3</xref> shows that the incidences of side effects were higher in the SG group than in SCG and other groups. COS reduces these side effects caused by sitagliptin.</p></sec><sec sec-type="methods"><title>qRT-PCR analysis</title><p>qRT-PCR analysis showed that the relative mRNA level of resistin was lower in SCG than SG after 1-day culture (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="f5-tcrm-13-739">Figure 5A</xref>). Comparatively, the relative mRNA level of CRP was lower in SCG than SG and other groups after 2-day culture (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="f5-tcrm-13-739">Figure 5B</xref>). Relative mRNA level of TNF-&#x003b1; was lower in SCG than SG and other groups after 1-day culture (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="f5-tcrm-13-739">Figure 5C</xref>). In contrast, the relative mRNA level of adiponectin was higher in SCG than SG and other groups after 1-day culture (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="f5-tcrm-13-739">Figure 5D</xref>).</p></sec><sec sec-type="methods"><title>Western blot analysis</title><p>Western blot analysis showed results similar to the qRT-PCR analysis. Relative protein level of resistin was lower in SCG than in SG and other groups after 1-day culture (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="f6-tcrm-13-739">Figure 6A</xref>). Comparatively, the relative protein level of CRP was lower in SCG than SG and other groups after 2-day culture (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="f6-tcrm-13-739">Figure 6B</xref>). Relative protein level of TNF-&#x003b1; was lower in SCG than SG and other groups after 1-day culture (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="f6-tcrm-13-739">Figure 6C</xref>). In contrast, the relative protein level of adiponectin was higher in SCG than SG and other groups after 1-day culture (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="f6-tcrm-13-739">Figure 6D</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Glycemic control is an important issue for the therapy of T2DM. In the present experiment, the combination therapy of sitagliptin and COS shows better glycemic control efficacy in elderly patients with T2DM when compared with the usage of only one kind of medicine. Combination therapy causes significant decreases in BMI (<xref ref-type="fig" rid="f2-tcrm-13-739">Figure 2A</xref>) and HbA1c &#x0003e;2.0% (<xref ref-type="fig" rid="f2-tcrm-13-739">Figure 2B</xref>).</p><p>The use of a combined treatment improves glycemic and weight control in most subjects with T2DM. Meanwhile, the levels of C peptide, &#x003b2;-cell function index, and adiponectin are also increased. Theoretically, although both groups have similar diabetes prevalence, there are significant statistical differences in adiposity, HOMA-IR and blood pressure, lipid profile, and other biochemical characteristics among the four groups, while SCG shows better therapeutic results than SG. All the changes are beneficial to the therapy of T2DM by using different treatment strategies.</p><p>The present findings indicated that combined therapy shows higher efficiency for controlling glucose level of patients in SCG than in SG. The results also suggest that COS can improve therapeutic results of sitagliptin for patients having glycemic levels that are difficult to control. Thus, combination therapy was superior in SCG for the elderly patients with T2DM when compared with the patients from the SG group. One important aspect that should be noted is that all subjects in the SCG group received combined therapy; however, combined therapy involves oral intake of the agents two times a day and reduces fasting and postprandial glucose. COS promotes glycemic control in T2DM subjects with difficulty in controlling the glycemic value. It has complementary functions with sitagliptin in the therapy of T2DM.</p><p>Similarly, BMI reduction was also observed in combined therapy (<xref ref-type="table" rid="t1-tcrm-13-739">Table 1</xref>). On the other hand, HbA1c levels decreased more significantly in SCG than in the SG group compared with levels prior to the trial (<xref ref-type="table" rid="t1-tcrm-13-739">Table 1</xref>); since this decrease was consistent with the reduction in body weight (<xref ref-type="table" rid="t1-tcrm-13-739">Table 1</xref>), it indicated that the observed weight reduction is a reliable means to achieve glycemic control effectively. Weight loss occurred continuously in the SCG group that received combined therapy. Meanwhile, better glycemic control and overall system effect were also observed. Considering the key factor of obesity in the pathophysiology of T2DM,<xref rid="b33-tcrm-13-739" ref-type="bibr">33</xref> it is necessary to reduce the risk factor by lowering the glucose level.</p><p>The combination therapy reduced the concentration of resistin, CRP, and TNF-&#x003b1; when compared with PG (<xref ref-type="fig" rid="f3-tcrm-13-739">Figure 3</xref>, <italic>P</italic>&#x0003c;0.05). On the other hand, it increased the concentration of adiponectin and GLP-1 (<xref ref-type="fig" rid="f3-tcrm-13-739">Figures 3D</xref> and <xref ref-type="fig" rid="f4-tcrm-13-739">4</xref>, <italic>P</italic>&#x0003c;0.05). Resistin level is associated with oxidative stress, thromboxane-dependent platelet activation and inflammatory activities, and a key determinant of atherothrombosis. Its evaluated level may increase the risk of diabetes.<xref rid="b34-tcrm-13-739" ref-type="bibr">34</xref> High-level CRP and TNF-&#x003b1; are also important risk factors of diabetes.<xref rid="b35-tcrm-13-739" ref-type="bibr">35</xref>,<xref rid="b36-tcrm-13-739" ref-type="bibr">36</xref> Adiponectin is one kind of adipokines that play a critical role in regulating insulin secretion and glucose and lipid metabolism in diabetic patients.<xref rid="b37-tcrm-13-739" ref-type="bibr">37</xref> GLP-1 promotes insulin secretion and demonstrates a protective effect for T2DM patients by controlling oxidative stress generation.<xref rid="b38-tcrm-13-739" ref-type="bibr">38</xref> The combination of sitagliptin and COS may ameliorate diabetes by affecting the levels of these molecules.</p><p>Comparatively, sitagliptin and COS show similar efficacy for glycemic control in elderly patients with T2DM when compared to patients in the PG group (<xref ref-type="table" rid="t2-tcrm-13-739">Table 2</xref>). There are no significant differences for the decreases in BMI (<xref ref-type="fig" rid="f2-tcrm-13-739">Figure 2A</xref>) and HbA1c &#x0003e;2.0% (<xref ref-type="fig" rid="f2-tcrm-13-739">Figure 2B</xref>) between SC and CG groups. In similar cases, there are no significant differences for CRP and TNF-&#x003b1; either (<xref ref-type="table" rid="t2-tcrm-13-739">Table 2</xref>). Resistin level is higher in CG than in SG while the adiponectin level is higher in SG than in CG (<xref ref-type="table" rid="t2-tcrm-13-739">Table 2, <italic>P</italic></xref>&#x0003c;0.05). COS is therefore not superior to sitagliptin in diabetes therapy but it can improve the therapeutic results of sitagliptin.</p><p>After long-term use of sitagliptin, most elderly T2DM patients experienced side effects including fatigue, cough, headache, hypoglycemia, loss of consciousness, constipation, nausea, vomiting, and diarrhea. These symptoms were in agreement with previous reports that side effects of fatigue,<xref rid="b9-tcrm-13-739" ref-type="bibr">9</xref> cough,<xref rid="b9-tcrm-13-739" ref-type="bibr">9</xref> headache,<xref rid="b25-tcrm-13-739" ref-type="bibr">25</xref> hypoglycemia,<xref rid="b26-tcrm-13-739" ref-type="bibr">26</xref> loss of consciousness,<xref rid="b26-tcrm-13-739" ref-type="bibr">26</xref> constipation,<xref rid="b27-tcrm-13-739" ref-type="bibr">27</xref> nausea,<xref rid="b27-tcrm-13-739" ref-type="bibr">27</xref> vomiting,<xref rid="b27-tcrm-13-739" ref-type="bibr">27</xref> and diarrhea<xref rid="b28-tcrm-13-739" ref-type="bibr">28</xref> are associated with long-term sitagliptin therapy. COS reduces these side effects and is beneficial to medical therapy of T2DM.</p><p>To explore the molecular mechanism for the functions of COS in the therapy of T2DM, human pancreatic cancer cell lines 3T3-L1 and 3T3-F442A were treated with sitagliptin or COS. Results showed that COS reduced the levels of resistin, CRP, and TNF-&#x003b1; and increased the level of adiponectin (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="f5-tcrm-13-739">Figures 5</xref> and <xref ref-type="fig" rid="f6-tcrm-13-739">6</xref>). Combined with the results from the clinical test, these findings suggest that COS may ameliorate T2DM by affecting the levels of resistin, CRP, and TNF-&#x003b1;, and increasing the level of adiponectin.</p></sec><sec><title>Conclusion</title><p>We explored the role of COS in elderly T2MD patients who received sitagliptin. SCG group showed better results than SG and other groups for controlling glycemic values. The combined treatment resulted in a higher increase in the concentration of adiponectin and higher decrease of the concentrations of CRP, resistin, and TNF-&#x003b1; in SCG than in the SG group (<italic>P</italic>&#x0003c;0.05). This combined treatment showed effective therapeutic results for elderly T2DM patients and should be developed as a potential option for their T2DM therapy.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-tcrm-13-739"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilden</surname><given-names>JL</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name></person-group><article-title>Non-ICU hospital care of diabetes mellitus in the elderly population</article-title><source>Curr Diab Rep</source><year>2015</year><volume>15</volume><issue>5</issue><fpage>26</fpage><pub-id pub-id-type="pmid">25772641</pub-id></element-citation></ref><ref id="b2-tcrm-13-739"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wild</surname><given-names>S</given-names></name><name><surname>Roglic</surname><given-names>G</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Sicree</surname><given-names>R</given-names></name><name><surname>King</surname><given-names>H</given-names></name></person-group><article-title>Global prevalence of diabetes: estimates for the year 2000 and projections for 2030</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><issue>5</issue><fpage>1047</fpage><lpage>1053</lpage><pub-id pub-id-type="pmid">15111519</pub-id></element-citation></ref><ref id="b3-tcrm-13-739"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bramlage</surname><given-names>P</given-names></name><name><surname>Gitt</surname><given-names>AK</given-names></name><name><surname>Binz</surname><given-names>C</given-names></name><name><surname>Krekler</surname><given-names>M</given-names></name><name><surname>Deeg</surname><given-names>E</given-names></name><name><surname>Tschope</surname><given-names>D</given-names></name></person-group><article-title>Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia</article-title><source>Cardiovasc Diabetol</source><year>2012</year><volume>11</volume><fpage>122</fpage><pub-id pub-id-type="pmid">23039216</pub-id></element-citation></ref><ref id="b4-tcrm-13-739"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordier</surname><given-names>L</given-names></name><name><surname>Buysschaert</surname><given-names>M</given-names></name><name><surname>Bauduceau</surname><given-names>B</given-names></name><etal/></person-group><article-title>Predicting factors of hypoglycaemia in elderly type 2 diabetes patients: contributions of the GERODIAB study</article-title><source>Diabetes Metab</source><year>2015</year><volume>41</volume><issue>4</issue><fpage>301</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">25845279</pub-id></element-citation></ref><ref id="b5-tcrm-13-739"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suresh</surname><given-names>PS</given-names></name><name><surname>Srinivas</surname><given-names>NR</given-names></name><name><surname>Mullangi</surname><given-names>R</given-names></name></person-group><article-title>A concise review of the bioanalytical methods for the quantitation of sitagliptin, an important dipeptidyl peptidase-4 (DPP4) inhibitor, utilized for the characterization of the drug</article-title><source>Biomed Chromatogr</source><year>2016</year><volume>30</volume><issue>5</issue><fpage>749</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">26873580</pub-id></element-citation></ref><ref id="b6-tcrm-13-739"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldshtein</surname><given-names>I</given-names></name><name><surname>Karasik</surname><given-names>A</given-names></name><name><surname>Melzer-Cohen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: a real-world evidence study</article-title><source>J Diabetes Complications</source><year>2016</year><volume>30</volume><issue>7</issue><fpage>1354</fpage><lpage>1359</lpage><pub-id pub-id-type="pmid">27320183</pub-id></element-citation></ref><ref id="b7-tcrm-13-739"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Khalifa</surname><given-names>H</given-names></name><name><surname>Mostafa</surname><given-names>DK</given-names></name><name><surname>El Sharkawy</surname><given-names>A</given-names></name></person-group><article-title>Suppression of connective tissue growth factor mediates the renoprotective effect of sitagliptin rather than pioglitazone in type 2 diabetes mellitus</article-title><source>Life Sci</source><year>2016</year><volume>153</volume><fpage>180</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">27049870</pub-id></element-citation></ref><ref id="b8-tcrm-13-739"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shankar</surname><given-names>RR</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Golm</surname><given-names>GT</given-names></name><etal/></person-group><article-title>A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus</article-title><source>Int J Clin Pract</source><year>2015</year><volume>69</volume><issue>6</issue><fpage>626</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">25652751</pub-id></element-citation></ref><ref id="b9-tcrm-13-739"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baraniuk</surname><given-names>JN</given-names></name><name><surname>Jamieson</surname><given-names>MJ</given-names></name></person-group><article-title>Rhinorrhea, cough and fatigue in patients taking sitagliptin</article-title><source>Allergy Asthma Clin Immunol</source><year>2010</year><volume>6</volume><issue>1</issue><fpage>8</fpage><pub-id pub-id-type="pmid">20462426</pub-id></element-citation></ref><ref id="b10-tcrm-13-739"><label>10</label><element-citation publication-type="journal"><article-title>Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer</article-title><source>Prescrire Int</source><year>2009</year><volume>18</volume><issue>101</issue><fpage>115</fpage><pub-id pub-id-type="pmid">19637427</pub-id></element-citation></ref><ref id="b11-tcrm-13-739"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>D-H</given-names></name><name><surname>Vo</surname><given-names>T-S</given-names></name><name><surname>Ngo</surname><given-names>D-N</given-names></name><etal/></person-group><article-title>Biological effects of chitosan and its derivatives</article-title><source>Food Hydrocoll</source><year>2015</year><volume>51</volume><fpage>200</fpage><lpage>216</lpage></element-citation></ref><ref id="b12-tcrm-13-739"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>F</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name></person-group><article-title>Controllable antioxidative xylan&#x02013;chitosan Maillard reaction products used for lipid food storage</article-title><source>Carbohydr Polym</source><year>2013</year><volume>91</volume><issue>1</issue><fpage>428</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">23044153</pub-id></element-citation></ref><ref id="b13-tcrm-13-739"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>GQ</given-names></name><name><surname>Leite Pereira</surname><given-names>C</given-names></name><name><surname>Castro</surname><given-names>F</given-names></name><etal/></person-group><article-title>Anti-inflammatory chitosan/poly-&#x003b3;-glutamic acid nanoparticles control inflammation while remodeling extracellular matrix in degenerated intervertebral disc</article-title><source>Acta Biomater</source><year>2016</year><volume>42</volume><fpage>168</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">27321188</pub-id></element-citation></ref><ref id="b14-tcrm-13-739"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karahaliloglu</surname><given-names>Z</given-names></name><name><surname>Kilicay</surname><given-names>E</given-names></name><name><surname>Denkbas</surname><given-names>EB</given-names></name></person-group><article-title>Antibacterial chitosan/silk sericin 3D porous scaffolds as a wound dressing material</article-title><source>Artif Cells Nanomed Biotechnol</source><comment>Epub</comment><year>2016</year><month>7</month><day>9</day></element-citation></ref><ref id="b15-tcrm-13-739"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerch</surname><given-names>G</given-names></name></person-group><article-title>The potential of chitosan and its derivatives in prevention and treatment of age-related diseases</article-title><source>Mar Drugs</source><year>2015</year><volume>13</volume><issue>4</issue><fpage>2158</fpage><lpage>2182</lpage><pub-id pub-id-type="pmid">25871293</pub-id></element-citation></ref><ref id="b16-tcrm-13-739"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cobrado</surname><given-names>L</given-names></name><name><surname>Silva-Dias</surname><given-names>A</given-names></name><name><surname>Azevedo</surname><given-names>MM</given-names></name><name><surname>Pina-Vaz</surname><given-names>C</given-names></name><name><surname>Rodrigues</surname><given-names>AG</given-names></name></person-group><article-title>In vivo antibiofilm effect of cerium, chitosan and hamamelitannin against usual agents of catheter-related bloodstream infections</article-title><source>J Antimicrob Chemother</source><year>2013</year><volume>68</volume><issue>1</issue><fpage>126</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">22991425</pub-id></element-citation></ref><ref id="b17-tcrm-13-739"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Jo</surname><given-names>SH</given-names></name><name><surname>Ha</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Effect of long-term supplementation of low molecular weight chitosan oligosaccharide (GO2KA1) on fasting blood glucose and HbA1c in db/db mice model and elucidation of mechanism of action</article-title><source>BMC Complement Altern Med</source><year>2014</year><volume>14</volume><fpage>272</fpage><pub-id pub-id-type="pmid">25074485</pub-id></element-citation></ref><ref id="b18-tcrm-13-739"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Ahn</surname><given-names>HY</given-names></name><name><surname>Kwak</surname><given-names>JH</given-names></name><etal/></person-group><article-title>The effects of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes</article-title><source>Food Funct</source><year>2014</year><volume>5</volume><issue>10</issue><fpage>2662</fpage><lpage>2669</lpage><pub-id pub-id-type="pmid">25222285</pub-id></element-citation></ref><ref id="b19-tcrm-13-739"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>SY</given-names></name><name><surname>Kwon</surname><given-names>YI</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Apostolidis</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>YC</given-names></name></person-group><article-title>Antidiabetic effect of chitosan oligosaccharide (GO2KA1) is mediated via inhibition of intestinal alpha-glucosidase and glucose transporters and PPAR</article-title><source>BioFactors</source><year>2017</year><volume>43</volume><issue>1</issue><fpage>90</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">27388525</pub-id></element-citation></ref><ref id="b20-tcrm-13-739"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skwarczynski</surname><given-names>M</given-names></name><name><surname>Ghaffar</surname><given-names>AK</given-names></name><name><surname>Giddam</surname><given-names>AK</given-names></name><name><surname>Batzloff</surname><given-names>M</given-names></name><name><surname>Good</surname><given-names>M</given-names></name><name><surname>Toth</surname><given-names>I</given-names></name></person-group><article-title>Highly immunogenic trimethyl chitosan-based delivery system for intranasal lipopeptide vaccines against group A streptococcus</article-title><source>Curr Drug Deliv</source><comment>Epub</comment><year>2016</year><month>7</month><day>21</day></element-citation></ref><ref id="b21-tcrm-13-739"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousef</surname><given-names>M</given-names></name><name><surname>Pichyangkura</surname><given-names>R</given-names></name><name><surname>Soodvilai</surname><given-names>S</given-names></name><name><surname>Chatsudthipong</surname><given-names>V</given-names></name><name><surname>Muanprasat</surname><given-names>C</given-names></name></person-group><article-title>Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action</article-title><source>Pharmacol Res</source><year>2012</year><volume>66</volume><issue>1</issue><fpage>66</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">22475725</pub-id></element-citation></ref><ref id="b22-tcrm-13-739"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennhart</surname><given-names>N</given-names></name><name><surname>Fukamizo</surname><given-names>T</given-names></name><name><surname>Brzezinski</surname><given-names>R</given-names></name><name><surname>Lacombe-Harvey</surname><given-names>ME</given-names></name><name><surname>Letzel</surname><given-names>T</given-names></name></person-group><article-title>Oligosaccharide hydrolysis by chitosanase enzymes monitored by real-time electrospray ionization-mass spectrometry</article-title><source>J Biotechnol</source><year>2008</year><volume>134</volume><issue>3&#x02013;4</issue><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">18359118</pub-id></element-citation></ref><ref id="b23-tcrm-13-739"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>General Assembly of the World Medical Association</collab></person-group><article-title>World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects</article-title><source>J Am Coll Dent</source><year>2014</year><volume>81</volume><issue>3</issue><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">25951678</pub-id></element-citation></ref><ref id="b24-tcrm-13-739"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelgau</surname><given-names>MM</given-names></name><name><surname>Thompson</surname><given-names>TJ</given-names></name><name><surname>Herman</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited</article-title><source>Diabetes Care</source><year>1997</year><volume>20</volume><issue>5</issue><fpage>785</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">9135943</pub-id></element-citation></ref><ref id="b25-tcrm-13-739"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arjona Ferreira</surname><given-names>JC</given-names></name><name><surname>Corry</surname><given-names>D</given-names></name><name><surname>Mogensen</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial</article-title><source>Am J Kidney Dis</source><year>2013</year><volume>61</volume><issue>4</issue><fpage>579</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">23352379</pub-id></element-citation></ref><ref id="b26-tcrm-13-739"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>Y</given-names></name><name><surname>Oyama</surname><given-names>J</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effects of sitagliptin beyond glycemic control: focus on quality of life</article-title><source>Cardiovasc Diabetol</source><year>2013</year><volume>12</volume><fpage>35</fpage><pub-id pub-id-type="pmid">23432786</pub-id></element-citation></ref><ref id="b27-tcrm-13-739"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Gou</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Zhai</surname><given-names>SD</given-names></name></person-group><article-title>Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>8</issue><fpage>e103798</fpage><pub-id pub-id-type="pmid">25089625</pub-id></element-citation></ref><ref id="b28-tcrm-13-739"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Hong</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name></person-group><article-title>Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials</article-title><source>Drug Des Devel Ther</source><year>2014</year><volume>8</volume><fpage>2283</fpage><lpage>2294</lpage></element-citation></ref><ref id="b29-tcrm-13-739"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>DJ</given-names></name><name><surname>Norrie</surname><given-names>J</given-names></name><name><surname>Caslake</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><issue>5</issue><fpage>1596</fpage><lpage>1600</lpage><pub-id pub-id-type="pmid">11978661</pub-id></element-citation></ref><ref id="b30-tcrm-13-739"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Uysal</surname><given-names>KT</given-names></name><name><surname>Becherer</surname><given-names>JD</given-names></name><name><surname>Arner</surname><given-names>P</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name></person-group><article-title>Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><issue>6</issue><fpage>1876</fpage><lpage>1883</lpage><pub-id pub-id-type="pmid">12031976</pub-id></element-citation></ref><ref id="b31-tcrm-13-739"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Uji</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association between reduction of plasma adiponectin levels and risk of bacterial infection after gastric cancer surgery</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>3</issue><fpage>e56129</fpage><pub-id pub-id-type="pmid">23520452</pub-id></element-citation></ref><ref id="b32-tcrm-13-739"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shehzad</surname><given-names>A</given-names></name><name><surname>Iqbal</surname><given-names>W</given-names></name><name><surname>Shehzad</surname><given-names>O</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name></person-group><article-title>Adiponectin: regulation of its production and its role in human diseases</article-title><source>Hormones</source><year>2012</year><volume>11</volume><issue>1</issue><fpage>8</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">22450341</pub-id></element-citation></ref><ref id="b33-tcrm-13-739"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadzadeh</surname><given-names>G</given-names></name><name><surname>Zarghami</surname><given-names>N</given-names></name></person-group><article-title>Hypoadiponectinemia in obese subjects with type II diabetes: a close association with central obesity indices</article-title><source>J Res Med Sci</source><year>2011</year><volume>16</volume><issue>6</issue><fpage>713</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">22091299</pub-id></element-citation></ref><ref id="b34-tcrm-13-739"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santilli</surname><given-names>F</given-names></name><name><surname>Liani</surname><given-names>R</given-names></name><name><surname>Di Fulvio</surname><given-names>P</given-names></name><etal/></person-group><article-title>Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus</article-title><source>Thromb Haemost</source><year>2016</year><volume>116</volume><issue>6</issue><fpage>1089</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">27709225</pub-id></element-citation></ref><ref id="b35-tcrm-13-739"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korovkin</surname><given-names>VS</given-names></name></person-group><article-title>&#x00420;&#x00435;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0044f; &#x00421;-&#x00440;&#x00435;&#x00430;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00431;&#x00435;&#x0043b;&#x0043a;&#x00430; &#x00443; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432; &#x00441; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x00438; &#x00441;&#x00430;&#x00445;&#x00430;&#x00440;&#x0043d;&#x0044b;&#x0043c; &#x00434;&#x00438;&#x00430;&#x00431;&#x00435;&#x00442;&#x0043e;&#x0043c; [The C-reactive protein reaction in patients with tuberculosis and diabetes mellitus]</article-title><source>Probl Tuberk</source><year>1968</year><volume>46</volume><issue>7</issue><fpage>90</fpage><lpage>91</lpage><comment>Russian</comment></element-citation></ref><ref id="b36-tcrm-13-739"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziamajidi</surname><given-names>N</given-names></name><name><surname>Nasiri</surname><given-names>A</given-names></name><name><surname>Abbasalipourkabir</surname><given-names>R</given-names></name><name><surname>Sadeghi Moheb</surname><given-names>S</given-names></name></person-group><article-title>Effects of garlic extract on TNF-alpha expression and oxidative stress status in the kidneys of rats with STZ + nicotinamide-induced diabetes</article-title><source>Pharm Biol</source><year>2017</year><volume>55</volume><issue>1</issue><fpage>526</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">27937047</pub-id></element-citation></ref><ref id="b37-tcrm-13-739"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlik</surname><given-names>A</given-names></name><name><surname>Teler</surname><given-names>J</given-names></name><name><surname>Maciejewska</surname><given-names>A</given-names></name><name><surname>Sawczuk</surname><given-names>M</given-names></name><name><surname>Safranow</surname><given-names>K</given-names></name><name><surname>Dziedziejko</surname><given-names>V</given-names></name></person-group><article-title>Adiponectin and leptin gene polymorphisms in women with gestational diabetes mellitus</article-title><source>J Assist Reprod Genet</source><year>2017</year><volume>34</volume><issue>4</issue><fpage>511</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">28050671</pub-id></element-citation></ref><ref id="b38-tcrm-13-739"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceriello</surname><given-names>A</given-names></name><name><surname>Esposito</surname><given-names>K</given-names></name><name><surname>Testa</surname><given-names>R</given-names></name><name><surname>Bonfigli</surname><given-names>AR</given-names></name><name><surname>Marra</surname><given-names>M</given-names></name><name><surname>Giugliano</surname><given-names>D</given-names></name></person-group><article-title>The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an &#x0201c;endothelial resistance&#x0201d; to glucagon-like peptide 1 in diabetes</article-title><source>Diabetes Care</source><year>2011</year><volume>34</volume><issue>3</issue><fpage>697</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">21273492</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-tcrm-13-739" position="float"><label>Figure 1</label><caption><p>MALDI-TOF MS analysis of COS.</p><p><bold>Note:</bold> The main products for DP were DP3, DP4, and DP5 when potassium adduct ions were calculated in MALDI-TOF.</p><p><bold>Abbreviations:</bold> MALDI-TOF, matrix-assisted laser desorption/ionization&#x02013;time-of-flight; COS, chitosan oligosaccharide; DP, degree of polymerization; MS, mass spectrometry.</p></caption><graphic xlink:href="tcrm-13-739Fig1"/></fig><fig id="f2-tcrm-13-739" position="float"><label>Figure 2</label><caption><p>Changes of mean values of (<bold>A</bold>) BMI and (<bold>B</bold>) HbAlc (%) between SCG and SG T2DM patients in a 42-week follow-up.</p><p><bold>Note:</bold> *<italic>P</italic>&#x0003c;0.05 versus PG.</p><p><bold>Abbreviations:</bold> BMI, body mass index; HbAlc, hemoglobin A1c; SCG, sitagliptin and chitosan oligosaccharide group; CG, chitosan oligosaccharide group; SG, sitagliptin group; T2DM, type 2 diabetes mellitus; PG, placebo group.</p></caption><graphic xlink:href="tcrm-13-739Fig2"/></fig><fig id="f3-tcrm-13-739" position="float"><label>Figure 3</label><caption><p>Changes of mean concentrations of (<bold>A</bold>) resistin (ng/mL), (<bold>B</bold>) C-reactive protein (mg/L), (<bold>C</bold>) TNF-&#x003b1; (pg/mL), and (<bold>D</bold>) adiponectin (pg/mL) between SCG and SG groups in a 42-week follow-up.</p><p><bold>Note:</bold> *<italic>P</italic>&#x0003c;0.05 versus PG.</p><p><bold>Abbreviations:</bold> SCG, sitagliptin and chitosan oligosaccharide group; CG, chitosan oligosaccharide group; SG, sitagliptin group; PG, placebo group; TNF, tumor necrosis factor.</p></caption><graphic xlink:href="tcrm-13-739Fig3"/></fig><fig id="f4-tcrm-13-739" position="float"><label>Figure 4</label><caption><p>Serum concentration of GLP-1 in different groups.</p><p><bold>Notes:</bold> Data presented as mean &#x000b1; SD. <sup>a</sup><italic>P</italic>&#x0003c;0.05 versus PG, <sup>b</sup><italic>P</italic>&#x0003c;0.05 versus SG, <sup>c</sup><italic>P</italic>&#x0003c;0.05 versus CG, and <sup>d</sup><italic>P</italic>&#x0003c;0.05 versus SCG.</p><p><bold>Abbreviations:</bold> GLP-1, glucagon-like peptide 1; SD, standard deviation; SCG, sitagliptin and chitosan oligosaccharide group; CG, chitosan oligosaccharide group; SG, sitagliptin group; PG, placebo group.</p></caption><graphic xlink:href="tcrm-13-739Fig4"/></fig><fig id="f5-tcrm-13-739" position="float"><label>Figure 5</label><caption><p>Real-time qPCR analysis of relative mRNA levels of (<bold>A</bold>) resistin, (<bold>B</bold>) C-reactive protein, (<bold>C</bold>) TNF-&#x003b1;, and (<bold>D</bold>) adiponectin between SCG and SG groups in human pancreatic cancer cell lines 3T3-L1 and 3T3-F442A.</p><p><bold>Note:</bold>
<sup>a</sup><italic>P</italic>&#x0003c;0.05 versus PG, <sup>b</sup><italic>P</italic>&#x0003c;0.05 versus SG, <sup>c</sup><italic>P</italic>&#x0003c;0.05 versus CG, and <sup>d</sup><italic>P</italic>&#x0003c;0.05 versus SCG.</p><p><bold>Abbreviations:</bold> SCG, sitagliptin and chitosan oligosaccharide group; CG, chitosan oligosaccharide group; SG, sitagliptin group; PG, placebo group; qPCR, quantitative polymerase chain reaction; TNF, tumor necrosis factor.</p></caption><graphic xlink:href="tcrm-13-739Fig5"/></fig><fig id="f6-tcrm-13-739" position="float"><label>Figure 6</label><caption><p>Western blot analysis of relative protein levels of (<bold>A</bold>) resistin, (<bold>B</bold>) C-reactive protein, (<bold>C</bold>) TNF-&#x003b1;, and (<bold>D</bold>) adiponectin between SCG and SG groups in human pancreatic cancer cell lines 3T3-L1 and 3T3-F442A.</p><p><bold>Note:</bold>
<sup>a</sup><italic>P</italic>&#x0003c;0.05 versus PG, <sup>b</sup><italic>P</italic>&#x0003c;0.05 versus SG, <sup>c</sup><italic>P</italic>&#x0003c;0.05 versus CG, and <sup>d</sup><italic>P</italic>&#x0003c;0.05 versus SCG.</p><p><bold>Abbreviations:</bold> SCG, sitagliptin and chitosan oligosaccharide group; CG, chitosan oligosaccharide group; SG, sitagliptin group; PG, placebo group; TNF, tumor necrosis factor.</p></caption><graphic xlink:href="tcrm-13-739Fig6"/><graphic xlink:href="tcrm-13-739Fig6a"/></fig><table-wrap id="t1-tcrm-13-739" position="float"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics of patients</th><th valign="top" align="left" rowspan="1" colspan="1">SG (n=50)</th><th valign="top" align="left" rowspan="1" colspan="1">CG (n=50)</th><th valign="top" align="left" rowspan="1" colspan="1">SCG (n=50)</th><th valign="top" align="left" rowspan="1" colspan="1">PG (n=50)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">69.1&#x000b1;8.4</td><td valign="top" align="left" rowspan="1" colspan="1">67.8&#x000b1;7.5</td><td valign="top" align="left" rowspan="1" colspan="1">68.9&#x000b1;8.8</td><td valign="top" align="left" rowspan="1" colspan="1">68.5&#x000b1;8.0</td><td valign="top" align="left" rowspan="1" colspan="1">0.246</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender, male, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">29 (58)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (62)</td><td valign="top" align="left" rowspan="1" colspan="1">30 (60)</td><td valign="top" align="left" rowspan="1" colspan="1">32 (64)</td><td valign="top" align="left" rowspan="1" colspan="1">0.683</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Race, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Han zhu</td><td valign="top" align="left" rowspan="1" colspan="1">44 (88)</td><td valign="top" align="left" rowspan="1" colspan="1">43 (86)</td><td valign="top" align="left" rowspan="1" colspan="1">44 (88)</td><td valign="top" align="left" rowspan="1" colspan="1">43 (86)</td><td valign="top" align="left" rowspan="1" colspan="1">0.766</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Manchu</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.727</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Mongolians</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Tibetans</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Weight (kg)</td><td valign="top" align="left" rowspan="1" colspan="1">85.6&#x000b1;16.4</td><td valign="top" align="left" rowspan="1" colspan="1">84.7&#x000b1;14.6</td><td valign="top" align="left" rowspan="1" colspan="1">86.7&#x000b1;15.8</td><td valign="top" align="left" rowspan="1" colspan="1">86.1&#x000b1;15.0</td><td valign="top" align="left" rowspan="1" colspan="1">0.145</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">28.2&#x000b1;2.9</td><td valign="top" align="left" rowspan="1" colspan="1">27.8&#x000b1;2.6</td><td valign="top" align="left" rowspan="1" colspan="1">28.5&#x000b1;2.7</td><td valign="top" align="left" rowspan="1" colspan="1">28.9&#x000b1;2.4</td><td valign="top" align="left" rowspan="1" colspan="1">0.532</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hemoglobin A1c (%)</td><td valign="top" align="left" rowspan="1" colspan="1">7.6&#x000b1;0.9</td><td valign="top" align="left" rowspan="1" colspan="1">7.9&#x000b1;0.9</td><td valign="top" align="left" rowspan="1" colspan="1">7.5&#x000b1;0.8</td><td valign="top" align="left" rowspan="1" colspan="1">7.6&#x000b1;0.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.107</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of diabetes (years)</td><td valign="top" align="left" rowspan="1" colspan="1">5.8&#x000b1;4.6</td><td valign="top" align="left" rowspan="1" colspan="1">5.5&#x000b1;4.2</td><td valign="top" align="left" rowspan="1" colspan="1">5.6&#x000b1;4.9</td><td valign="top" align="left" rowspan="1" colspan="1">5.7&#x000b1;4.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.642</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HR (beats/minute)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;24-hour</td><td valign="top" align="left" rowspan="1" colspan="1">76.8&#x000b1;14.2</td><td valign="top" align="left" rowspan="1" colspan="1">78.4&#x000b1;14.0</td><td valign="top" align="left" rowspan="1" colspan="1">77.4&#x000b1;15.1</td><td valign="top" align="left" rowspan="1" colspan="1">76.4&#x000b1;14.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.728</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Daytime</td><td valign="top" align="left" rowspan="1" colspan="1">81.2&#x000b1;12.3</td><td valign="top" align="left" rowspan="1" colspan="1">80.2&#x000b1;11.5</td><td valign="top" align="left" rowspan="1" colspan="1">80.8&#x000b1;13.5</td><td valign="top" align="left" rowspan="1" colspan="1">80.4&#x000b1;12.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.859</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Nighttime</td><td valign="top" align="left" rowspan="1" colspan="1">69.4&#x000b1;8.6</td><td valign="top" align="left" rowspan="1" colspan="1">67.6&#x000b1;9.0</td><td valign="top" align="left" rowspan="1" colspan="1">68.9&#x000b1;9.5</td><td valign="top" align="left" rowspan="1" colspan="1">66.5&#x000b1;8.4</td><td valign="top" align="left" rowspan="1" colspan="1">0.678</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;24-hour</td><td valign="top" align="left" rowspan="1" colspan="1">141.7&#x000b1;12.6</td><td valign="top" align="left" rowspan="1" colspan="1">130.6&#x000b1;11.2</td><td valign="top" align="left" rowspan="1" colspan="1">139.5&#x000b1;11.9</td><td valign="top" align="left" rowspan="1" colspan="1">134.5&#x000b1;10.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.554</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Daytime</td><td valign="top" align="left" rowspan="1" colspan="1">151.4&#x000b1;13.7</td><td valign="top" align="left" rowspan="1" colspan="1">153.2&#x000b1;13.2</td><td valign="top" align="left" rowspan="1" colspan="1">150.6&#x000b1;12.8</td><td valign="top" align="left" rowspan="1" colspan="1">147.6&#x000b1;11.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.762</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Nighttime</td><td valign="top" align="left" rowspan="1" colspan="1">140.8&#x000b1;14.2</td><td valign="top" align="left" rowspan="1" colspan="1">140.5&#x000b1;13.3</td><td valign="top" align="left" rowspan="1" colspan="1">142.4&#x000b1;13.6</td><td valign="top" align="left" rowspan="1" colspan="1">145.5&#x000b1;11.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.331</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;24-hour</td><td valign="top" align="left" rowspan="1" colspan="1">85.6&#x000b1;8.2</td><td valign="top" align="left" rowspan="1" colspan="1">86.6&#x000b1;7.5</td><td valign="top" align="left" rowspan="1" colspan="1">86.0&#x000b1;7.3</td><td valign="top" align="left" rowspan="1" colspan="1">86.7&#x000b1;7.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.426</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Daytime</td><td valign="top" align="left" rowspan="1" colspan="1">87.5&#x000b1;8.0</td><td valign="top" align="left" rowspan="1" colspan="1">86.2&#x000b1;7.4</td><td valign="top" align="left" rowspan="1" colspan="1">89.1&#x000b1;7.8</td><td valign="top" align="left" rowspan="1" colspan="1">85.9&#x000b1;7.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.584</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Nighttime</td><td valign="top" align="left" rowspan="1" colspan="1">79.4&#x000b1;8.2</td><td valign="top" align="left" rowspan="1" colspan="1">77.4&#x000b1;6.9</td><td valign="top" align="left" rowspan="1" colspan="1">78.9&#x000b1;6.6</td><td valign="top" align="left" rowspan="1" colspan="1">78.0&#x000b1;6.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.252</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Failing with single-drug treatment, n</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;BIA</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">0.677</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Exenatide</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0.829</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;MET</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">0.822</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-tcrm-13-739"><p><bold>Notes:</bold> Chi-square test and <italic>t</italic>-test were performed to compare the variance between two groups. There are significant statistic differences at <italic>P</italic>&#x0003c;0.05. Data presented as mean &#x000b1; SD unless indicated otherwise.</p></fn><fn id="tfn2-tcrm-13-739"><p><bold>Abbreviations:</bold> SCG, sitagliptin and chitosan oligosaccharide group; CG, chitosan oligosaccharide group; SG, sitagliptin group; PG, placebo group; BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; BIA, biphasic insulin aspart; MET, metformin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-tcrm-13-739" position="float"><label>Table 2</label><caption><p>Parameter changes after 42-week trial</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Parameters</th><th valign="top" align="left" rowspan="1" colspan="1">SG (N=50)</th><th valign="top" align="left" rowspan="1" colspan="1">CG (N=50)</th><th valign="top" align="left" rowspan="1" colspan="1">SCG (N=50)</th><th valign="top" align="left" rowspan="1" colspan="1">PG (N=50)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>t</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Weight (kg)</td><td valign="top" align="left" rowspan="1" colspan="1">84.4&#x000b1;15.7</td><td valign="top" align="left" rowspan="1" colspan="1">82.1&#x000b1;14.9</td><td valign="top" align="left" rowspan="1" colspan="1">82.0&#x000b1;17.6</td><td valign="top" align="left" rowspan="1" colspan="1">85.2&#x000b1;14.0</td><td valign="top" align="left" rowspan="1" colspan="1">1.79</td><td valign="top" align="left" rowspan="1" colspan="1">0.015</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">26.4&#x000b1;1.2</td><td valign="top" align="left" rowspan="1" colspan="1">26.8&#x000b1;1.4</td><td valign="top" align="left" rowspan="1" colspan="1">24.5&#x000b1;1.5</td><td valign="top" align="left" rowspan="1" colspan="1">28.6&#x000b1;1.9</td><td valign="top" align="left" rowspan="1" colspan="1">1.23</td><td valign="top" align="left" rowspan="1" colspan="1">0.027</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FBG (mmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">7.9&#x000b1;1.1</td><td valign="top" align="left" rowspan="1" colspan="1">8.0&#x000b1;1.0</td><td valign="top" align="left" rowspan="1" colspan="1">7.3&#x000b1;1.0</td><td valign="top" align="left" rowspan="1" colspan="1">8.6&#x000b1;1.3</td><td valign="top" align="left" rowspan="1" colspan="1">2.01</td><td valign="top" align="left" rowspan="1" colspan="1">0.018</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2hPG (mmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">12.4&#x000b1;1.5</td><td valign="top" align="left" rowspan="1" colspan="1">13.5&#x000b1;1.9</td><td valign="top" align="left" rowspan="1" colspan="1">10.4&#x000b1;1.7</td><td valign="top" align="left" rowspan="1" colspan="1">14.4&#x000b1;1.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.85</td><td valign="top" align="left" rowspan="1" colspan="1">0.022</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HbAlc (%)</td><td valign="top" align="left" rowspan="1" colspan="1">7.5&#x000b1;0.9</td><td valign="top" align="left" rowspan="1" colspan="1">7.0&#x000b1;0.8</td><td valign="top" align="left" rowspan="1" colspan="1">6.8&#x000b1;0.9</td><td valign="top" align="left" rowspan="1" colspan="1">8.7&#x000b1;0.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.74</td><td valign="top" align="left" rowspan="1" colspan="1">0.037</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TG (mmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">2.2&#x000b1;1.3</td><td valign="top" align="left" rowspan="1" colspan="1">2.4&#x000b1;1.1</td><td valign="top" align="left" rowspan="1" colspan="1">1.8&#x000b1;1.0</td><td valign="top" align="left" rowspan="1" colspan="1">2.6&#x000b1;1.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.75</td><td valign="top" align="left" rowspan="1" colspan="1">0.030</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TC (mmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">5.2&#x000b1;2.3</td><td valign="top" align="left" rowspan="1" colspan="1">5.5&#x000b1;1.8</td><td valign="top" align="left" rowspan="1" colspan="1">4.5&#x000b1;1.6</td><td valign="top" align="left" rowspan="1" colspan="1">6.0&#x000b1;1.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.63</td><td valign="top" align="left" rowspan="1" colspan="1">0.021</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDL (mmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">1.5&#x000b1;0.8</td><td valign="top" align="left" rowspan="1" colspan="1">1.4&#x000b1;0.6</td><td valign="top" align="left" rowspan="1" colspan="1">1.6&#x000b1;0.5</td><td valign="top" align="left" rowspan="1" colspan="1">1.4&#x000b1;0.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.23</td><td valign="top" align="left" rowspan="1" colspan="1">0.143</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDL (mmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">3.9&#x000b1;1.7</td><td valign="top" align="left" rowspan="1" colspan="1">3.6&#x000b1;1.1</td><td valign="top" align="left" rowspan="1" colspan="1">2.8&#x000b1;1.0</td><td valign="top" align="left" rowspan="1" colspan="1">4.5&#x000b1;1.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.81</td><td valign="top" align="left" rowspan="1" colspan="1">0.042</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FINS (pmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">124.6&#x000b1;45.7</td><td valign="top" align="left" rowspan="1" colspan="1">127.6&#x000b1;39.3</td><td valign="top" align="left" rowspan="1" colspan="1">119.4&#x000b1;37.9</td><td valign="top" align="left" rowspan="1" colspan="1">138.5&#x000b1;36.4</td><td valign="top" align="left" rowspan="1" colspan="1">0.97</td><td valign="top" align="left" rowspan="1" colspan="1">0.025</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HOMA-IR</td><td valign="top" align="left" rowspan="1" colspan="1">5.8&#x000b1;2.4</td><td valign="top" align="left" rowspan="1" colspan="1">6.0&#x000b1;2.4</td><td valign="top" align="left" rowspan="1" colspan="1">4.5&#x000b1;2.5</td><td valign="top" align="left" rowspan="1" colspan="1">6.3&#x000b1;2.9</td><td valign="top" align="left" rowspan="1" colspan="1">1.08</td><td valign="top" align="left" rowspan="1" colspan="1">0.031</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HOMA-IS</td><td valign="top" align="left" rowspan="1" colspan="1">80.3&#x000b1;54.2</td><td valign="top" align="left" rowspan="1" colspan="1">78.3&#x000b1;50.9</td><td valign="top" align="left" rowspan="1" colspan="1">91.6&#x000b1;43.8</td><td valign="top" align="left" rowspan="1" colspan="1">70.3&#x000b1;52.3</td><td valign="top" align="left" rowspan="1" colspan="1">2.97</td><td valign="top" align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fasting c peptide (nmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">1.2&#x000b1;0.5</td><td valign="top" align="left" rowspan="1" colspan="1">1.1&#x000b1;0.4</td><td valign="top" align="left" rowspan="1" colspan="1">1.1&#x000b1;0.3</td><td valign="top" align="left" rowspan="1" colspan="1">1.1&#x000b1;0.4</td><td valign="top" align="left" rowspan="1" colspan="1">0.11</td><td valign="top" align="left" rowspan="1" colspan="1">0.092</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2-hour postprandial c peptide (nmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">2.57&#x000b1;1.1</td><td valign="top" align="left" rowspan="1" colspan="1">2.84&#x000b1;1.2</td><td valign="top" align="left" rowspan="1" colspan="1">2.73&#x000b1;1.2</td><td valign="top" align="left" rowspan="1" colspan="1">2.86&#x000b1;1.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.44</td><td valign="top" align="left" rowspan="1" colspan="1">0.074</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Resistin (ng/mL)</td><td valign="top" align="left" rowspan="1" colspan="1">11.34&#x000b1;0.51</td><td valign="top" align="left" rowspan="1" colspan="1">13.18&#x000b1;0.44</td><td valign="top" align="left" rowspan="1" colspan="1">7.15&#x000b1;0.36</td><td valign="top" align="left" rowspan="1" colspan="1">16.22&#x000b1;0.38</td><td valign="top" align="left" rowspan="1" colspan="1">3.21</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adiponectin (pg/mL)</td><td valign="top" align="left" rowspan="1" colspan="1">158.5&#x000b1;7.6</td><td valign="top" align="left" rowspan="1" colspan="1">142.5&#x000b1;8.5</td><td valign="top" align="left" rowspan="1" colspan="1">172.1&#x000b1;10.8</td><td valign="top" align="left" rowspan="1" colspan="1">123.4&#x000b1;7.6</td><td valign="top" align="left" rowspan="1" colspan="1">1.22</td><td valign="top" align="left" rowspan="1" colspan="1">0.044</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">C-reactive protein (mg/L)</td><td valign="top" align="left" rowspan="1" colspan="1">5.1&#x000b1;0.6</td><td valign="top" align="left" rowspan="1" colspan="1">5.4&#x000b1;0.5</td><td valign="top" align="left" rowspan="1" colspan="1">4.2&#x000b1;0.4</td><td valign="top" align="left" rowspan="1" colspan="1">6.2&#x000b1;0.5</td><td valign="top" align="left" rowspan="1" colspan="1">3.64</td><td valign="top" align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TNF-&#x003b1; (pg/mL)</td><td valign="top" align="left" rowspan="1" colspan="1">312.7&#x000b1;19.9</td><td valign="top" align="left" rowspan="1" colspan="1">326.4&#x000b1;17.3</td><td valign="top" align="left" rowspan="1" colspan="1">280.1&#x000b1;16.4</td><td valign="top" align="left" rowspan="1" colspan="1">345.6&#x000b1;18.2</td><td valign="top" align="left" rowspan="1" colspan="1">3.89</td><td valign="top" align="left" rowspan="1" colspan="1">0.005</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-tcrm-13-739"><p><bold>Notes:</bold> ANOVA was performed to compare the variance among four groups. Data presented as mean &#x000b1; SD. There are significant statistic differences at <italic>P</italic>&#x0003c;0.05.</p></fn><fn id="tfn4-tcrm-13-739"><p><bold>Abbreviations:</bold> SCG, sitagliptin and chitosan oligosaccharide group; CG, chitosan oligosaccharide group; SG, sitagliptin group; PG, placebo group; ANOVA, analysis of variance; SD, standard deviation; BMI, body mass index; FBG, fasting blood glucose; HbAlc, hemoglobin A1c; TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FINS, fasting insulin; HOMA-IR, insulin resistance index; HOMA-IS, insulin secre tory activity; TNF, tumor necrosis factor; 2hPG, two-hour plasma glucose.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-tcrm-13-739" position="float"><label>Table 3</label><caption><p>Side effects after 42-week trial</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Never<break/>n (%)</th><th valign="top" align="left" rowspan="1" colspan="1">Rarely<break/>n (%)</th><th valign="top" align="left" rowspan="1" colspan="1">Sometimes<break/>n (%)</th><th valign="top" align="left" rowspan="1" colspan="1">Very often<break/>n (%)</th><th valign="top" align="left" rowspan="1" colspan="1">Always<break/>n (%)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Fatigue</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SG</td><td valign="top" align="left" rowspan="1" colspan="1">8 (16)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (24)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (28)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CG</td><td valign="top" align="left" rowspan="1" colspan="1">24 (48)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (36)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SCG</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (16)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PG</td><td valign="top" align="left" rowspan="1" colspan="1">20 (40)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cough</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SG</td><td valign="top" align="left" rowspan="1" colspan="1">20 (40)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CG</td><td valign="top" align="left" rowspan="1" colspan="1">35 (70)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SCG</td><td valign="top" align="left" rowspan="1" colspan="1">25 (50)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (24)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (22)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PG</td><td valign="top" align="left" rowspan="1" colspan="1">30 (60)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (24)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (12)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Headache</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SG</td><td valign="top" align="left" rowspan="1" colspan="1">16 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (16)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (40)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CG</td><td valign="top" align="left" rowspan="1" colspan="1">27 (54)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (34)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SCG</td><td valign="top" align="left" rowspan="1" colspan="1">19 (38)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PG</td><td valign="top" align="left" rowspan="1" colspan="1">25 (50)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (14)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypoglycemia</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SG</td><td valign="top" align="left" rowspan="1" colspan="1">22 (44)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (18)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (12)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CG</td><td valign="top" align="left" rowspan="1" colspan="1">30 (60)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (28)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SCG</td><td valign="top" align="left" rowspan="1" colspan="1">26 (52)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (24)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (18)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PG</td><td valign="top" align="left" rowspan="1" colspan="1">31 (62)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Loss of consciousness</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SG</td><td valign="top" align="left" rowspan="1" colspan="1">29 (58)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (22)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CG</td><td valign="top" align="left" rowspan="1" colspan="1">33 (66)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (24)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SCG</td><td valign="top" align="left" rowspan="1" colspan="1">34 (68)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (12)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PG</td><td valign="top" align="left" rowspan="1" colspan="1">36 (72)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (24)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Constipation</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SG</td><td valign="top" align="left" rowspan="1" colspan="1">16 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (24)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (18)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CG</td><td valign="top" align="left" rowspan="1" colspan="1">20 (40)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SCG</td><td valign="top" align="left" rowspan="1" colspan="1">18 (36)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PG</td><td valign="top" align="left" rowspan="1" colspan="1">19 (38)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (34)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (24)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nausea</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SG</td><td valign="top" align="left" rowspan="1" colspan="1">25 (50)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (12)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CG</td><td valign="top" align="left" rowspan="1" colspan="1">32 (64)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (28)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SCG</td><td valign="top" align="left" rowspan="1" colspan="1">28 (56)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PG</td><td valign="top" align="left" rowspan="1" colspan="1">38 (76)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (22)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vomiting</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SG</td><td valign="top" align="left" rowspan="1" colspan="1">26 (52)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (22)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (14)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CG</td><td valign="top" align="left" rowspan="1" colspan="1">38 (76)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (18)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SCG</td><td valign="top" align="left" rowspan="1" colspan="1">35 (70)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PG</td><td valign="top" align="left" rowspan="1" colspan="1">40 (80)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (16)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diarrhea</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SG</td><td valign="top" align="left" rowspan="1" colspan="1">20 (40)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (16)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CG</td><td valign="top" align="left" rowspan="1" colspan="1">24 (48)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;SCG</td><td valign="top" align="left" rowspan="1" colspan="1">22 (44)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (28)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (18)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PG</td><td valign="top" align="left" rowspan="1" colspan="1">32 (64)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-tcrm-13-739"><p><bold>Notes:</bold> Before the experiments, all patients had no side effects. There are significant statistic differences at <italic>P</italic>&#x0003c;0.05.</p></fn><fn id="tfn6-tcrm-13-739"><p><bold>Abbreviations:</bold> SCG, sitagliptin and chitosan oligosaccharide group; CG, chitosan oligosaccharide group; SG, sitagliptin group; PG, placebo group; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></floats-group></article>